Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John Bridgewater, Julien Edeline, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 127-140
Open Access | Times Cited: 324

Showing 1-25 of 324 citing articles:

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, et al.
Liver International (2023) Vol. 43, Iss. 8, pp. 1803-1812
Open Access | Times Cited: 62
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 17
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103488-103488
Open Access | Times Cited: 16
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Yixiang Gu, Ruifeng Yang, Yang Zhang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 6
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 2
Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
Taiyu Shang, Tianyi Jiang, Tao Lü, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study
Anita Balakrishnan, Petros Barmpounakis, Nikolaos Demiris, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101951-101951
Open Access | Times Cited: 30
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 27
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
Xiaoxue Ren, Mingle Huang, Weixiang Weng, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101277-101277
Open Access | Times Cited: 24
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, et al.
Clinical Epidemiology (2023) Vol. Volume 15, pp. 1069-1085
Open Access | Times Cited: 24
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 14
Advances in targeted therapy of cholangiocarcinoma
Yuhang Li, Jianfeng Yu, Yujing Zhang, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 13
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113587-113587
Open Access | Times Cited: 10
Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring
Ningyuan Wen, Dingzhong Peng, Xianze Xiong, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2752-2752
Open Access | Times Cited: 9
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gaël S. Roth, Loïc Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114000-114000
Open Access | Times Cited: 8
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection
James Yu, Aiwu Ruth He, Mahmoud Ouf, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access | Times Cited: 1
Potential Influence of Antifungal-drug Resistant Pathogens in Patients with Cholangiocarcinoma and the Application of Nanoparticle Mechanisms as Novel Antifungal and Anticancer Agents
Conrad Chibunna Achilonu, Tsepo Ramatla, Maleke Maleke, et al.
Current Clinical Microbiology Reports (2025) Vol. 12, Iss. 1
Open Access | Times Cited: 1
The importance of preclinical models for cholangiocarcinoma drug discovery
Florian Primavesi, Felix J. Krendl, Rupert Oberhuber, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access | Times Cited: 1
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies
Lorenza Rimassa, Shahid A. Khan, Bas Groot Koerkamp, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101171-101171
Open Access | Times Cited: 1
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
Irene García Megías, Ludmila Santiago Almeida, Adriana K. Calapaquí Terán, et al.
Annals of Nuclear Medicine (2025)
Open Access | Times Cited: 1
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities
Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2323336-e2323336
Open Access | Times Cited: 20
Fibroblasts in liver cancer: functions and therapeutic translation
Silvia Affò, Aveline Filliol, Gregory J. Gores, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 748-759
Open Access | Times Cited: 19
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study
Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, et al.
European Journal of Cancer (2023) Vol. 187, pp. 174-184
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top